On July 1, Moderna rose 5.21% in regular trading, trading at $72.21/share, with turnover of $138 million. The rally was driven by continued positive momentum from multiple recent catalysts, including the company's Science Day event and sustained expectations for flu vaccine approval.

On June 25, Moderna held its Science Day, disclosing for the first time its in-vivo CAR-T project mRNA-6007, targeting B-cell mediated autoimmune diseases with plans to enter clinical trials next year. The event also showcased multiple pipeline programs including tumor vaccines, cancer prevention vaccines, and an AI-powered R&D platform. The market has increasingly viewed Moderna as transitioning from a single-product vaccine company to a platform biopharmaceutical enterprise. Following the event, Piper Sandler raised its target price to $77 from $69 maintaining an Overweight rating, while Jefferies raised its target to $53 from $45 maintaining Hold.

Additionally, the FDA's advisory committee voted unanimously (9-0) in mid-June recommending approval of mRNA-1010, Moderna's seasonal influenza vaccine for adults aged 50 and older, with a final FDA decision expected by August 5. The company has also appointed a new Chief Commercial Officer and reorganized its structure to prepare for potential launches of up to three new vaccines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)